After completing one cycle of therapy, patients will be registered for randomization between intermittent and continuous dosing, provided that they were eligible for the initial step 1 registration and satisfy the following criteriaXx_NEWLINE_xXPatients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlinedXx_NEWLINE_xXPatient re-enrollment: This study permits the re-enrollment of a patient that has discontinued the study as a screen failure (ie, patient has not been dosed/has not been treated); if re-enrolled, the patient must be re-consented and satisfy all eligibility criteriaXx_NEWLINE_xXIf the study Sponsor decides to evaluate additional solid tumors, subjects must satisfy following criteria to be included in the study: Has a pathologically documented advanced solid tumor.Xx_NEWLINE_xXDose Escalation Portion: Patients must satisfy one of the following criteria:Xx_NEWLINE_xXDose Expansion Portion: Patients must satisfy one of the following criteria:Xx_NEWLINE_xXSubjects enrolled on the combination therapy phase must satisfy the above exclusion criteria and also the following:Xx_NEWLINE_xXEach patient must satisfy at least one of the following criteria:Xx_NEWLINE_xXPatient must also satisfy at least one of the following criteria:Xx_NEWLINE_xXPatient must also satisfy at least one of the following criteria:Xx_NEWLINE_xXSubjects must satisfy the following criteria to be enrolled in the study:Xx_NEWLINE_xXPatients must satisfy 1 of the following criteria for prior therapy:Xx_NEWLINE_xXLife expectancy ?3 months. Subjects must also satisfy the following inclusion criterion:Xx_NEWLINE_xXSubjects must satisfy the following criteria to be enrolled in the study:Xx_NEWLINE_xXSubjects must satisfy the following criteria to be enrolled into the study:Xx_NEWLINE_xXSubjects must satisfy the following criteria to be enrolled in the study:Xx_NEWLINE_xXThe patient must - at the time of re-induction - satisfy all the eligibility criteriaXx_NEWLINE_xXPatients must satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLEXx_NEWLINE_xXSatisfy at least one of the following criteriaXx_NEWLINE_xXPatients with isolated hepatic metastasis must satisfy a Clinical Risk Score of 3 or higherXx_NEWLINE_xXEnrollment in the SATISFY-SOS study (WUSTL IRB# 201203088, NCT02032030)Xx_NEWLINE_xXPatients with distant metastatic disease will be eligible if they satisfy all other conditionsXx_NEWLINE_xX